NCT07467837 Prevention of Stretch Marks in Expectant Mothers
| NCT ID | NCT07467837 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stratpharma AG |
| Condition | Pregnant Women |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2026-02-24 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2026-02-24 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PRIME Mothers is a national observational trial designed to evaluate patient outcomes with Stratamark® for the prevention of stretch marks during pregnancy and the postpartum period. The study is designed to fit seamlessly into routine clinical practice, with digital follow-up and home resupply, minimising clinic involvement.
Eligibility Criteria
Inclusion Criteria: * Pregnant women at any gestational age. * Participants who are in good health, including those that are carrying multiples, who are 18 years of age or older. * Confirmed absence of pre-existing stretch marks on the abdomen. * Agree to apply Stratamark according to the prescribed protocol for the duration of the study. * Ability to complete remote online surveys via an electronic device. * Provide signed informed consent to participate in the study. Exclusion Criteria: * Visible stretch marks on the abdomen prior to enrollment. * Pre-existing skin conditions (e.g., eczema, psoriasis), on the abdomen that could interfere with product application or assessment of stretch marks. * Known hypersensitivity or allergy to any of the ingredients in Stratamark. * Use of other topical treatments on the abdomen, including but not limited to oils, or creams targeting stretch mark prevention. * Participants unable to give informed consent, or unable to have written consent provided on their behalf. * Participants who cannot administer the treatment or have the treatments administered as per the directions for use.
Contact & Investigator
Dr Philip Hall, MBBS, MRMed, FRANZCOG, FRCOG,
PRINCIPAL INVESTIGATOR
St. Andrews War Memorial Hospital
Frequently Asked Questions
Who can join the NCT07467837 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Pregnant Women. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07467837 currently recruiting?
Yes, NCT07467837 is actively recruiting participants. Contact the research team at azurlinden@stratpharma.com for enrollment information.
Where is the NCT07467837 trial being conducted?
This trial is being conducted at Brisbane, Australia.
Who is sponsoring the NCT07467837 clinical trial?
NCT07467837 is sponsored by Stratpharma AG. The principal investigator is Dr Philip Hall, MBBS, MRMed, FRANZCOG, FRCOG, at St. Andrews War Memorial Hospital. The trial plans to enroll 10,000 participants.